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oortic Stenosis (AS)
eviews. The following reviews were published during the
ear: “Insights into degenerative aortic valve (AV) disease”
1) and “Genomics: The next step to elucidate the etiology
f calcific aortic stenosis (AS)” (2).
tate-of-the-art papers. In 2008, Ross published “Trans-
eptal left heart catheterization: a 50 year odyssey” (3).
Comment. Transseptal left heart catheterization, a pio-
eering procedure, was developed by John Ross Jr. when he
as a surgical intern on a research rotation. He changed his
pecialty and went on to become a distinguished figure in
ardiovascular medicine.
Another article published at this time is “Emerging
pplications for Transseptal Catheterization: Old Tech-
iques for New Procedures” (4).
rading of AS severity; inconsistencies of echocardio-
raphic criteria. The consistency of 3 echocardiographic
riteria for severe AS (aortic valve area [AVA] 1.0 m2 [or
0.6 cm2/m2], mean gradient [MG] 40 mm Hg or peak
ow [Vmax] 4 m/s) used in the Guidelines were evaluated
n 3,483 echocardiographic studies performed in 2,427
atients with normal left ventricular (LV) systolic function
nd calculated AVA of 2 cm2 performed from 1994 to
004 (5). There were “clinically significant” differences (Fig.
, Table 1).
Comment. This important and useful study highlights
nconsistencies in criteria for severe AS. An accompanying
ditorial (6) discusses the importance of this study and
robable reasons for the differences. The problem may be
he guidelines. In this study, it would have been better to
ave measured cardiac output (CO). The authors acknowl-
dge that calculating stroke volume from echocardiography
s “often difficult.” They assumed a CO of 6 l/min, heart rate
rom the Griffith Center, Division of Cardiovascular Medicine, Department of
edicine, LACUSC Medical Center, Keck School of Medicine at University of
outhern California, Los Angeles, California. Dr. Rahimtoola has received honoraria
or educational lectures from the American College of Cardiology Foundation;
merican College of Physicians; University of California Los Angeles; University of
alifornia Irvine; Cornell University; Creighton University; Thomas Jefferson Uni-
ersity; Cedars-Sinai Medical Center; Harvard Medical School; University of Wis-
onsin; University of Hawaii; Cardiologists Association of Hong Kong, China; ATS;
t. Jude Medical; Carbomedics; Merck; Pfizer; and Edwards Life Sciences. This
eview covers articles published from July 2007 to June 2008.1
Manuscript received September 18, 2008; revised manuscript received January 21,
009, accepted February 6, 2009.f 80 beats/min, and a systolic ejection time of 0.33 s. (Also
ee Gutierrez-Chico et al. [10] cited below.)
ncreasing blood pressure (BP) affects measured AS
everity. In 22 patients, BP was increased by handgrip or
henylephrine infusion from a mean of 99  8 mm Hg to
21  10 mm Hg (p  0.001) (7). The AVA decreased
rom 1.15  0.32 cm2 to 1.09  0.33 cm2 (p  0.02).
Comment. Flow was not measured but was calculated.
he clinical situation arises in patients with severe or
orderline severe AS, low gradient, and hypertension. The
linical problem is as follows: To what level, by what
ethod, and how rapidly should BP be lowered before the
easurements are repeated?
ardiac multidetector computed tomography (MDCT)
o assess the severity of AS. Forty consecutive patients
cheduled for aortic valve replacement (AVR) had echocar-
iography, MDCT, and coronary angiography within a
ime span of 1 week (8). The AVA as measured by MDCT
nd echocardiography was 0.87  0.22 cm2 versus 0.81 
.20 cm2 (p  0.01; r  0.77, and p  0.01, respectively).
ean difference was 0.06  0.15 cm2. The authors found
hat MDCT correctly identified 26 of 33 patients (79%)
ith coronary artery stenosis and overestimated 3 patients
ith 50% stenosis.
here is pressure recovery best measured? In a pulse
uplicator with flow rates of 2 to 5 l/min and orifice areas
etween 0.32 and 2.85 cm2, pressure recovery data were best
easured 5 cm above AV (9), assuming that AV is a circular
rifice, proximal aorta is circular without sinuses or bends,
nd flow is axially symmetric.
he measurement of AVA by RT3D. In 41 patients with
S, AVA was measured with the use of Gorlin’s equation,
akki’s formula, Doppler continuity equation (CE), 2D
impson’s volumetric method, and by the real-time
-dimensional echocardiography (RT3D). Cardiac output
as measured by the thermodilution technique (10). RT3D
ad the best linear association and absolute agreement with
orlin’s method of all noninvasive methods (r  0.902;
ntraclass correlation coefficient of 0.846) (Fig. 2). RT3D
nderestimates AVA (95% confidence interval [CI]: 0.084
o 0.193) and also grades most efficiently the severity of AS
s mild, moderate, or severe (weighted kappa 0.932). The
se of receiver-operating characteristic curves showed the
ptimal cutoff point to consider severe AS “remains close to
cm2 (1.06 cm2).”
(
p
A
E
M
l
M
w
(
c
p
d
y
9
C
m
g
r
a
o
h
A
t
S
p
L
M
p
a
c
t
o
A
w
o
t
1
a
1
a
s
a
p
t
s
(
o
d
A
d
PAE
R
A
m
1895JACC Vol. 53, No. 20, 2009 Rahimtoola
May 19, 2009:1894–1908 Year in Valvular Heart DiseaseComment. AVA by Gorlin’s formula is very good if data
pressures and CO) are both obtained and calculated ap-
ropriately.
ortic valve replacement (AVR). “LOW FLOW/LOW GRADI-
NT” AS. A total of 217 consecutive patients in a European
ulticenter Study with severe AS (AVA 1.0 cm2), low
eft ventricular ejection fraction (LVEF) (35%), and low
G (30 mm Hg) underwent AVR. Operative mortality
as 20% from 1990 to 1999 and 10% from 2000 to 2005
11). On multivariate analysis, very low MG and multivessel
oronary artery disease (MVD) were predictors of excess
erioperative mortality. In the subgroup who underwent
obutamine stress echocardiography, on multivariate anal-
sis, a lack of “contractile reserve” (odds ratio [OR]: 4.4;
5% CI: 1.5 to 17.5; p  0.03) and MVD (OR: 6.0; 95%
I: 1.5 to 2.4, p  0.01) were strong predictors of operative
ortality. The 5-year survival was 49  4%. Lower MG,
reater score on the European system for cardiac operative
isk evaluation (EuroSCORE), previous atrial fibrillation,
nd MVD were identified as independent predictors of
verall long-term mortality (Fig. 3).
Figure 1 Relationship of Valve Areas in Aortic Stenosis
Aortic valve area from the Gorlin equation versus mean gradient (left) and peak flo
Quadrants are based on cut-off values for severe aortic stenosis as stated in the
indicate consistent grading but not those in the upper right and lower left quadran
ercentage of Patients Diagnosed With Severeo tic Stenosis Depending o Whichcho ardiographic Criterion Was Used
Table 1
Percentage of Patients Diagnosed With Severe
Aortic Stenosis Depending on Which
Echocardiographic Criterion Was Used
Guidelines
Recommendations Parameter
Patients With
Severe AS (%)
ACC/AHA AVA 1.0 cm2 69
ESC AVA/BSA 0.6 cm2/m2 76
ACC/AHA (Otto) Vmax 4.0 m/s 45
ACC/AHA  Pm 40 mm Hg 40
eprinted, with permission, from Minners et al. (5).
ACC/AHA  American College of Cardiology/American Heart Association; AS  aortic stenosis;n
VA  aortic valve area; BSA  body surface area; ESC  European Society of Cardiology;  Pm
ean pressure gradient; Vmax  peak flow velocity.Comment. A diagnosis of hibernating myocardium would
ave been an important part of pre-operative testing (12).
lso, it would be best to perform right heart catheterization
o document cardiac index/stroke index were “low.”
evere AS, normal LVEF, and low MG. A total of 215
atients had isolated AS, normal sinus rhythm, and normal
VEF. Patient characteristics and outcome in those with
G 30 and 30 mm Hg (13) are shown in Table 2. The
atients with MG30 mm Hg had a lower referral to AVR
nd a greater death rate both before and after AVR.
Comment. This was a large study in which cardiac
atheterization was performed. It documents in detail pa-
ient characteristics and hemodynamics in the 2 subgroups
f patients.
symptomatic patients with severe AS. Of 622 patients
ho were initially asymptomatic between 1984 and 1995,
nly 263 of 622 patients who subsequently had surgery at
he authors’ institution are described. Of the 263 patients,
66 had developed symptoms and 97 remained asymptom-
tic (14); operative mortality in the 2 subgroups was 2% and
%, respectively. In those who had symptoms or were
symptomatic, the survival of patients who underwent
urgery was better than those who did not (Fig. 4).
Comment. This study of asymptomatic patients has many
reas of concern, which have been described in detail
reviously (15). These data are from highly selected pa-
ients. 1) Of 694 patients in the database, 72 with more
evere AS had AVR initially, leaving 622 for follow-up
16,17). 2) Although 352 patients had subsequent surgery,
nly the 263 who had surgery at the authors’ institution are
escribed. Moreover, the criteria for selecting patients for
VR was not provided and were not pre-determined. To
etermine that AVR was better than no AVR, data are
city (right). The predicted and fitted curves of the study population are shown.
t guidelines. Data pairs positioned in the upper left and lower right quadrants
printed, with permission, from Minners et al. (5).w velo
curren
ts. Reeeded on baseline characteristics of operated versus non-
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Year in Valvular Heart Disease May 19, 2009:1894–1908perated patients in both the symptomatic and asymptom-
tic subgroups, characteristics that were not provided.
he EuroSCORE overestimates operative mortality of
alve surgery. A total of 1,299 patients had either isolated
alve surgery procedures or valve surgery plus coronary
rtery bypass graft surgery (CABG) (18). The observed
ortality in the 2 groups was 2.8% and 6.8%, respectively.
ortality predicted by the New York model (19) was 3.4%
nd 6.2%, respectively, which was much closer to the actual
bserved mortality. Mortality predicted by the use of Eu-
oSCORE (20,21) was 6.1% and 7.8%.
A total of 731 patients with a EuroSCORE of 7 or
reater underwent isolated AVR (22). A minimally invasive
pproach was used in 469 (64.2%). The mean EuroSCORE
as 9.7 (median 10); 731 patients had a EuroSCORE 7,
f whom 332 had a EuroSCORE10. The actual observed
perative mortality was 7.8% and that predicted by logistic
uroSCORE was 17.2%. Freedom from all-cause death
including hospital mortality) was 72.4% at 5 years (Fig. 5).
Comment. The EuroSCORE was first published in 1999
Figure 2 Relationship of Aortic Valve Area by the Use of Gorlin
Linear regression of the aortic valve areas by echocardiographic (echo) methods a
represents the regression line, 95% confidence intervals for the mean (interrupted
rupted, outer bounds). Reprinted, with permission, from Gutierrez-Chico et al (10).20). It was based on a dataset of 13,302 patients, of whom Epproximately 60% were patients undergoing CABG, 30%
ndergoing valve surgery, and 10% other surgical proce-
ures. Cardiac surgery for valve disease is constantly im-
roving; for example, New York State Cardiac Surgery data
how that hospital mortality from 2001 to 2003 was lower
han from 1998 to 2000 (23).
redictors of poorer survival after AVR. Of 3,049 pa-
ients who underwent AVR for AS from 1991 to 2004,
redictors of decreased survival (24) were severe LV hyper-
rophy, severity of AS, use of smaller prosthesis, and
entricular dysfunction.
ortic Regurgitation (AR)
re-operative LV end-systolic diameter index (ESDI)
25 mm/m2 is a better predictor of outcomes than ESD
50 mm. A total of 147 consecutive patients age 52  12
ears underwent surgery for chronic severe AR for symp-
oms in 107 (76.3%) and 40 (23.7%) for LV dysfunction
parameters” (25). The comparison of ESDI 25 mm to
rmula to That by Noninvasive and Invasive Techniques
ki’s formula (x-axis) with that by Gorlin’s equation (y-axis). Center line (yellow)
, inner bounds), and 95% confidence intervals for the individuals (red, inter-
2-dimensional; 3D  3-dimensional.’s Fo
nd Hak
yellow
2D SD 50 mm showed that the use of ESDI better
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May 19, 2009:1894–1908 Year in Valvular Heart Diseasedentified symptomatic patients, asymptomatic patients
ith LV dysfunction, patients with worse LVEF after
urgery, and overall rate of mortality.
linical outcome in asymptomatic patients with AR. A
otal of 251 patients were enrolled from 1991 to 2003 and
ollowed until their death or 2006, whichever came first.
he patients were 60  17 years of age with a diastolic
lood pressure of 71  12 mm Hg which, in the severe AR
roup, was 64  13 mm Hg. A history of hypertension was
resent in 49% (26). A total of 93 patients were categorized
s severe AR on the basis of regurgitant volume 60
l/beat or effective regurgitant orifice 30 mm2 from
Figure 3 5-Year Survival in Patients With Low Gradient Aortic S
5-year survival after aortic valve replacement in patients with low gradient severe a
presence of multivessel coronary artery disease (MVD) (left) and mean aortic valv
atient Characteristicsi h Low and High Gradients
Table 2 Patient CharacteristicsWith Low and High Gradients
Mean Gradient
p Value<30 mm Hg >30 mm Hg
n 47 168 —
Age (yrs) 79 9 76 10 0.20
Hypertension 43 (91%) 107 (64%) 0.0004
LVEDVI (ml/m2) 47 9 56 12 0.0001
LVEF 0.62 0.09 0.65 0.09 0.03
SV index (ml/beats/m2) 37 12 41 11 0.002
Cardiac output (l/min) 4.4 1.1 5.2 1.3 0.0001
SVR (dyne·cm·s5) 2,163 754 1,879 528 0.05
AVA (cm2) 0.85 0.19 0.68 0.17 0.0001
AVA (cm2/m2) 0.46 0.09 0.37 0.09 0.0001
AV mean gradient (mm Hg) 23 5 50 15 0.0001
Coronary artery disease 36 (76%) 138 (82%) 0.58
Death before AVR 9 (19%) 16 (9.5%) 0.05
AVR 15 (33%) 97 (58%) 0.01
Death after AVR 4 (27%) 5 (5%) —
ata from Barasch et al. (13).
AV  aortic valve; AVR  aortic valve replacement; LVEDVI  left ventricular end-diastolicp
olume index; LVEF  left ventricular ejection fraction; SV  stroke volume; SVR  systemic
ascular index; other abbreviations as in Table 1.oppler echocardiographic studies. When severe AR versus
ild AR was compared, 10-year survival was lower (69 
% vs. 92 4%, p 0.05) and cardiac events (cardiac death,
eart failure, and new atrial fibrillation) were higher (63 8%
s. 21 8%, p 0.0001). Patients with moderate AR showed
no significant reduction of cardiac events after surgery (p
.92),” but patients with severe AR had a reduction in
ardiac events: linearized yearly rates were 11.2% “under
edical management” and 2.3% with surgery (p  0.002).
Comment. There are many concerns with this type of
atural history study (15). For example: 1) At entry into the
tudy, patients were in their 60s and 70s, but there is no
nformation about lipid profile and the percent of patients
ho on entry had coronary arteriography and significantly
bstructive coronary artery disease (CAD). Did none have
AD at entry? Ten years later, when patients were in their
0s and 80s, did none develop or have progression of CAD
hat could have led to heart failure, atrial fibrillation, or
eath? 2) What was “medical management”? How effective
as it in controlling abnormalities?
Other concerns include the following: 1) Likely, the
0-year survival in the moderate group was not significantly
ower than in the severe group (75  6% vs. 69  9%); the
value was not provided. This finding adds to the possi-
ility that AR was not the cause of the event(s). 2) The
iastolic blood pressure was 64  13 mm Hg. Thus, AR
as not severe in many patients. The American Society of
chocardiography (27,28) recommends: a) 3 quantitative
riteria to define severity of AR. The severity of AR was
udged by only 1 of 2 quantitative criteria—why not both?
as there discordance between the 2 criteria? What about
he third criterion? b) Correction of LV dimensions and
olumes for body size. These measurements were not
sis
tenosis according to the pre-operative
ient (right). Reprinted, with permission, from Levy et al. (11).teno
ortic s
e gradresented, which also raises concerns about the severity of
A
8
p
k
fi
a
s
B
A
y
C
y
a
y
c
e
p
(
d
w

1
A
m
l
1898 Rahimtoola JACC Vol. 53, No. 20, 2009
Year in Valvular Heart Disease May 19, 2009:1894–1908R. 3) Cardiac surgery was stated to be performed in 80 of
1 patients for AR, but 11 had surgery for physician and/or
atient preference, 11 for “aortic aneurysm,” and an un-
nown number “for LV enlargement,” which was unde-
ned. In chronic severe AR, LV had to have been enlarged
t baseline and the amount of additional increase of LV
ize/volume to warrant AVR was not described.
icuspid Aortic Valve (BAV)
symptomatic patients with BAV; low event rate at 20
ears. A total of 212 asymptomatic residents of Olmsted
ounty, Minnesota, with BAV, 65% male, ages 32  20
ears between 1980 and 1999, with LVEF 0.63  0.05 and
Figure 4 Survival in Asymptomatic Patients With Severe Aortic
Survival of “all patients” diagnosed with asymptomatic severe aortic stenosis.
Reprinted, with permission, from Brown et al. (14). AVR  aortic valve replacemen
Figure 5 Survival After Aortic Valve Replacement in Older Patie
Survival of “high-risk” patients with severe aortic stenosis after traditional surgicalbsent or mild AS and/or AR were followed for up to 20
ears (29). The AV degeneration was subjectively scored for
alcification, thickening, and mobility reduction (0 to 3 for
ach). Events at 20 years are shown in Table 3. Independent
redictors for cardiovascular events were age 50 years
OR: 3.0; 95% CI: 1.5 to 5.7; p 0.01); valve degeneration at
iagnosis (OR: 2.4; 95% CI: 1.2 to 4.5; p  0.016) (Fig. 6)
ith 70% events at 10 years; and baseline ascending aorta
40 mm for surgery for aortic dilation (OR: 10.8; 95% CI:
.8 to 77.3; p  0.01).
ortic dilation has distinct patterns. Thoracic aortic
orphology in 64 patients with BAV was determined at 10
evels with the use of computed tomographic angiography or
osis
 symptoms.
t High Risk
valve replacement. Reprinted, with permission, from Grossi et al. (22).Sten
t; symnts a
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May 19, 2009:1894–1908 Year in Valvular Heart Diseaseagnetic resonance angiography (30). Patients in the dif-
erent clusters needed different surgical techniques of aortic
urgery (Fig. 7).
Comment. Patients with BAV may need surgery for the
alve, the aorta, or both. It is important to evaluate and
easure the ascending aorta at the annulus, sinuses, and
inotubular junction, at the largest size in the whole of the
scending aorta and in the arch of the aorta because it helps
o determine the need for surgery on the aorta and also the
urgical procedure that will need to be done.
ong-term survival after the Bentall procedure. A total
f 206 patients underwent composite aortic root replace-
ent (i.e., button-Bentall procedure). Hospital mortality
as 2.9%, stroke rate was 1.9% (31); risk factors for these
vents were clot or atheroma (p  0.02) and age 65 years
p  0.05). Follow-up ranged from 5 to 18 years; 5- and
0-year survival rates were 93% and 89%, respectively.
0-Year Outcomes in Patientsith Bicuspid Aortic V lv (Age 32  10 Years)
Table 3 20-Year Outcomes in PatientsWith Bicuspid Aortic Valve (Age 32  10 Years)
Incidence of Outcomes (%)
Death 10 3
Heart failure 7 2
New cardiac symptoms 26 4
Cardiovascular medical events 33 5
Aortic valve surgery 24 4
Ascending aortic surgery 5 2
Any cardiovascular surgery 27 4
Aortic dissection None
Total cardiovascular (medical or surgical) events 42 5
eprinted, with permission, from Michelena et al. (29).
Figure 6 Bicuspid Aortic Valve: Long-Term Outcome in Asympto
Bicuspid aortic valve: incidence of aortic valve surgery (left) and of medical events
ration (blue; score 3). Medical events included cardiac death, heart failure, new
Michelena et al. (29).itral Regurgitation (MR)
ole of imaging. O’Gara et al. (32) provide a useful and
mportant description of the role of echocardiographic/
oppler imaging, including the importance of segmental
natomy in chronic “degenerative” MR.
ardiovascular magnetic resonance (CMR) of mitral
alve (MV) prolapse. CMR performed in 16 patients had
100% sensitivity and 100% specificity compared with the
se of transesophageal echocardiography (TTE) for the
-mm threshold for leaflet excursion into the left atrium
33). It was found that CMR showed larger and longer
ndexed posterior leaflet and larger index mitral annular
iameters. Late gadolinium enhancement (LGE) was
resent in 94% in the MV and mitral annulus and in the
apillary muscles in 10 of 16 patients (63%), which is
uggestive of fibrosis and which was associated with the
resence of complex ventricular arrhythmias.
Comment. This was a study with a small number of
atients. There was no information on coronary arterio-
raphic findings in the patients with LGE in the papillary
uscle. The etiology of LGE was not clear. The presence of
GE may be a clue to another etiological factor of MV
rolapse. Additional studies of CMR in MV prolapse are
eeded, especially in those with complex ventricular ar-
hythmias.
reater operative mortality for MV surgery in younger
omen. Of 24,977 patients (49% women) in the Society of
horacic Surgeons (STS) database (34), the operative mortal-
ty in women was 3.9% versus 2.4% for men. The incidence of
ll comorbidities also was greater. The adjusted female/male
ic Patients
t) in those with early valve deterioration (red; score 3) or no early valve deterio-
vascular symptoms, stroke, and endocarditis. Reprinted, with permission, frommat
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Year in Valvular Heart Disease May 19, 2009:1894–1908R for hospital mortality in the group ages 40 to 49 years was
.56 (95% CI: 1.31 to 5.01; p  0.0058) and in those ages 50
o 59 years was 1.95 (95% CI: 1.32 to 2.89; p  0.0009).
months is optimal timing for echocardiography/
oppler for MR after myocardial infarction. From base-
ine to 1 year, LV end-diastolic volume index increased from
6  15 ml/m2 to 63  19 ml/m2 (p  0.0001) (35); a
raded increase depending on MR at 3 months at which
ime the incidence of no MR was 21%, mild MR 32%, and
oderate/severe MR 60% (p  0.008). By multivariate
Figure 7 Bicuspid Aortic Valve:
Computed Tomography of the Aorta
Three-dimensional computed tomographic angiographic reconstruction of a
patient with bicuspid aortic valve. Ten sections (A to J) at which the aortic
diameter was measured are shown. In cluster I, 8 patients (13%) had involve-
ment of aortic root (A to C). In cluster II, 9 (14%) had involvement of the tubu-
lar portion of the ascending aorta (D and E). In cluster III, 18 (28%) had
involvement of the tubular portion of the ascending aorta and transverse aortic
arch aortic proximal and distal to takeoff of the innominate artery (E to G). In
cluster IV, 29 (45%) had diffuse involvement of the aortic root, ascending
aorta, and proximal aortic arch. Clusters I and IV, both of which involved the
aortic root involvement, accounted for 73% of the patients. Reprinted, with per-
mission, from Fazel et al. (30).nalysis, MR at 3 months but not at baseline was indepen- Rently associated with increased hospitalization and death at
median follow-up of 1,226 days.
urability of mitral valve repair (MVrep). A total of 348
atients had MVrep and “the classic techniques described by
arpentier and others were used” (36). Hospital mortality
as 1.6%. Survival at 5 and 10 years was 93  1.5% and
0.1  3.7%, respectively (Fig. 8). Survival was identical in
hose with Barlow’s disease and in fibroelastic deficiency.
o patient was lost to follow-up. The mean number of
ollow-up echocardiograms was 4.6 (range 2 to 16). At 1
onth, 98.7% of patients had no or trivial MR (0/4 to 1/4);
n Barlow’s disease, it was 97.1%, and in fibroelastic defi-
iency, it was 99.8%. The incidence of failing repair (free-
om from MR grade 2/4) was 82.2  3.7% at 5 years and
4.9  5.6% at 10 years (Table 4). At baseline, atrial
brillation was present in 22%.
At most recent follow-up, patients in New York Heart
ssociation (NYHA) functional classes I, II, III, and IV were
5%, 19%, 5%, and 1%, respectively. Warfarin anticoagulation
as given to 35% of patients. Freedom from thromboembolic
vents and/or anticoagulation-related bleeding was 93.5 
.5% at 5 years and 86.7  2.7% at 10 years.
Comment. Flameng et al. (36) have once again presented
areful, detailed results of MVrep. Follow-up included
requent echocardiograms, and results are reported as recur-
ences of MR and not as reoperation rates, which is a
ovable target. This study has important implications for
ype of MVrep, MV repair versus replacement, and also for
ndications of surgery in the asymptomatic patient. To be
oted, data on the pre-operative NYHA functional classes
nd MR severity were not provided.
utcomes after MVrep are similar to mitral valve re-
lacement (MVR). From 1985 to 2005, a total of 3,286
atients underwent primary operation for “degenerative” MR
37). Hospital mortality in 3,051 patients with MVrep was
.26% and for 235 patients with MVR was 2.1% (p  0.001).
atients undergoing MVR were older (70 12 years vs. 57
3 years) and had more complex valve pathology, symptoms,
nd LV dysfunction. In propensity-matched patients, survival
as similar (p  0.8) (i.e., at 5 years 86% vs. 83%, at 10 years
3% vs. 62%, and at 15 years 43% vs. 48%). Freedom from
eoperation also was similar (p  0.6) for MVrep at 5 and 10
ears was 95% and for MVR was 95 and 92%, respectively.
Comment. David (38), in discussing this article, stated
hat a subsequent analysis of his own data in propensity-
atched patients confirmed the aforementioned findings.
eoperation after MVrep. From January 1980 to January
005, a total of 4,024 patients in the same institution as the
forementioned study had MVrep for “degenerative” disease
ausing MR, and 188 (4.7%) underwent reoperation for
ecurrent MR (39). Reoperation for procedure-related
roblems occurred early (median 19 days) in 96 patients
nd, for valve-related problems, occurred later (median 5.4
ears) in 109 patients (p  0.0001). Mitral valve replace-
ent was performed in 64% and repeat MVrep in 36%.
epeat MVrep was performed in 65% of recent reopera-
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May 19, 2009:1894–1908 Year in Valvular Heart Diseaseions. After re-repair at 10 years, the incidence of second
e-repair was 7% and survival was 62%.
ricuspid Regurgitation (TR)
he incidence of TR in patients with constrictive peri-
arditis. TR was present in 185 of 261 (71%) patients who
ad pericardiectomy (40); TR was moderate to severe in 54
20%). Previous cardiac surgery and radiation were the cause
n 34 (63%) and 15 (28%), respectively. Moderate-to-severe
R versus none-to-mild TR was associated with a greater
perative mortality (13% vs. 4.3%; p  0.019); however,
xcluding those cases caused by radiation, operative mortal-
ty was similar. Five-year survival was poorer in those with
oderate-to-severe TR at 47% versus 87% in those with
ild TR. Tricuspid valve repair had no significant impact
n late survival.
nfective Endocarditis (IE)
igh mortality of dialysis patients undergoing valve
urgery. A total of 1,862 valvular procedures were recorded
n dialysis patients with IE in the STS database. Points were
ssigned for operative mortality risks (Table 5) (41). The
bserved mortality increased from 7.1% to 76% as risk score
oints increased from 0 to 10 (Table 6).
Figure 8 Recurrence of MR After Valve Repair
Linearized curves for recurrence of mitral regurgitation (MR) 2/4 after mitral valv
risk factors are nonuse of annuloplasty ring, nonuse of sliding plasty, or performan
mission, from Flameng et al. (36).
inearized Recurrence Rate% Per Year) for Re urren MR >2/4
Table 4 Linearized Recurrence Rate(% Per Year) for Recurrent MR >2/4
All Patients FED Barlow
Overall 3.2 2.6 6.0
Without surgical risk 2.4 2.2 2.9
With surgical risk 4.7 3.6 14.9
urgical risk indicates the nonuse of annuloplasty ring, nonuse of sliding plasty, or performance of
hordal shortening. Reprinted, with permission, from Flameng et al. (36).
MR  mitral regurgitation; FED  fibroelastic deficiency.
(Comment. In 50% of the patients, the risks ranged from
3% to 60%.
omograft valve not superior to conventional prosthesis.
f 127 consecutive patients, 54 (43%) were treated with
ortic homograft and 73 (57%) with conventional prosthesis
42). Homografts were inserted in 41 of 63 (65%) patients
ho had an annular abscess. Between the 2 types of
rostheses, hospital mortality was not significantly different
11% vs. 8%, p  0.6). By multivariate analysis, prosthetic
alve IE was associated with greater mortality (OR: 12.5;
5% CI: 1.4 to 114.2; p  0.001). The 10-year survival free
f end point (IE recurrence, noninfective prostheses dys-
unction, or long-term cardiovascular mortality) was 44 
0% and was not significantly different between the 2 types
f prostheses (p  0.2).
Comment. Studies are needed to better define patients
ho need a homograft. Should a homograft be necessary
nly in those with an abscess and/or with persistent sepsis?
ir in those with fibroelastic disease (left) and Barlow’s disease (right). Surgical
chordal shortening and for patients not having these factors. Reprinted, with per-
isk Scores for Mortality With Surgery inatients With Infective Endocarditis on Dialysis
Table 5 Risk Scores for Mortality With Surgery inPatients With Infective Endocarditis on Dialysis
Variable Point
Salvage status/cardiogenic shock 3
Double valve surgery 3
Age 60 yrs 2
Mitral valve only surgery 2
BSA 2.1 m2 2
Female sex 1
Active endocarditis type 1
Arrhythmia 1
otal risk score determined by summing all points. Reprinted, with permission, from Rankin et al.e repa
ce of41).
Abbreviations as in Table 1.
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Year in Valvular Heart Disease May 19, 2009:1894–1908ranscatheter Valve Therapy
osition statement for transcatheter valve implanta-
ion. In 2008, the European Association of Cardio-
horacic Surgery, the European Society of Cardiology, and
he European Association of Percutaneous Cardiovascular
nterventions (43) published a position statement on trans-
atheter valve implantation.
ndovascular resection of human aortic valves in situ. Per-
utaneous resection of the diseased native valve before the
ew valve is percutaneously implanted was performed in 10
uman cadavers (44).
ransarterial AV implantation. Percutaneous transfemo-
al AV implantation was performed in 50 high-risk severely
ymptomatic patients by use of the Cribier-Edwards 23-
nd 26-mm expandable valves (Edwards Lifesciences Inc.,
rvine, California). Mortality at 30 days was 12% in patients
n whom the logistic EuroSCORE was 28% (45). There
as a learning curve, and procedural success increased from
6% to 96% (Fig. 9). Valve area measured from echocardio-
rams increased from 0.6  0.2 cm2 to 1.7  0.4 cm2.
aravalvular regurgitation was mild, LVEF increased (p 
.001), and functional class improved (p  0.0001).
Comment. Retrograde implantation is a significant ad-
ance. The current model of the Edwards SAPIEN valve
ses the bovine pericardium with THERMA FIX, which in
he PERIMOUNT valve for traditional surgical AVR has a
ow rate of structural valve deterioration out to 15 to 20
ears (46). The SAPIEN valve was successfully delivered in
7 of 54 (87%) patients, the 30-day mortality was 7.4%, and
he major adverse cardiac rate was 16.7% (47).
Concern exists regarding the severity of AR after percu-
aneous valve insertion. In an earlier multicenter study with
he Cribier-Edwards valve the incidence of 3/4 AR was
common” (48). In this study, echocardiographic/Doppler
riteria for severity of AR were not quantitative as is
ecommended by the American Society of Echocardiogra-
hy. Left ventricular and femoral artery tracings raise
bserved Mortality With Surgery by Risk Scoren Pati nts With Infective Endocarditis on Dialysis
Table 6 Observed Mortality With Surgery by Risk Scorein Patients With Infective Endocarditis on Dialysis
Risk Score No. of Patients Mean Observed Mortality (%)
0 85 7.1
1 158 7.6
2 206 12.6
3 330 16.7
4 298 22.8
5 235 26.4
6 204 34.3
7 117 41.9
8 67 59.7
9 30 50.0
10 25 76.0
eprinted, with permission, from Rankin et al. (41).oncerns as discussed in Figure 10 (49).Percutaneous AV implantation was performed with the use
f a second-generation CoreValve 21-F catheter in 50 patients
nd 18-F third-generation catheter in 36 patients (CoreValve
nc., Irvine, California). The logistic EuroSCORE was 21.7 
2.6%, and 83% of patients were in NYHA functional
lasses III and IV. In 6 patients, misplacement of the valve
esulted in conversion to surgical AVR and, in 2 patients,
alcified AV could not be crossed. Procedural success was
4% (50). The 30-day mortality was 12%, and the incidence
f death, stroke, and myocardial infarction was 22%.
Comment. The CoreValve System seems to have a lot of
etal, appears bulky, and currently has only a 21-mm
ioprosthesis. It utilizes porcine pericardium whose rate of
VD is not known. Also, there was a high rate of procedural
ilation after valve implantation (28% of 76 valve implan-
ations) (51). The valve area post-procedure was not pro-
ided.
The 21-F CoreValve System (CoreValve, Paris, France)
as inserted under femoro-femoral cardiopulmonary bypass
upport in 10 high-risk patients (estimated mortality deter-
ined by a EuroSCORE of 32% for surgical AVR) (52).
he 30-day and 3-month mortalities were 20% and 30%,
espectively. The AVA increased from 0.57  0.19 cm2 to
.2  0.35 cm2 (p  0.0001), and the median NYHA
unctional class improved from III to II (p  0.01).
Comment. Post-procedure the mean valve area was only
.2 cm2!
A total of 66 consecutive patients age 70 years with
evere symptomatic AS were reported (53). Of 39 patients with
EuroSCORE 20%, AVA was 0.6  0.2 cm2 (0.4  0.1
m2/m2), MG was 47  14 mm Hg, and LVEF was 0.52 
.15. Pulmonary artery hypertension 60 mm Hg was
resent in 9% of patients who were considered at high risk
Figure 9 Learning Curve of
Percutaneous Aortic Valve Replacement
Survival was better (p  0.09) for the second 25 patients when compared with
the first 25 patients after percutaneous aortic valve replacement. Reprinted,
with permission, from Webb et al. (45).
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May 19, 2009:1894–1908 Year in Valvular Heart Diseaser inoperable for surgery. Twelve received percutaneous
APIEN valves (Edwards LifeSciences, Inc.). A total of 27
ad contraindications to percutaneous valve and received a
ariety of therapies. In the 12 who had the percutaneous
alve replacement, hospital mortality was 25%. A total of 31
atients had surgical AVR. In 27, the EuroSCORE was
20%, and 4 were considered at high risk for percutaneous
VR. The hospital mortality was 4%.
re endovascular valved stents suitable for all
atients? Thirty-five patients with severe AS who were
cheduled for AVR were studied. A braided nitinol self-
xpanded stent from Laboratories Perouse (Ivry-le-Temple,
rance) that was used was calibrated for implantation inside
circular orifice with a 20-mm diameter and was implanted
n a triangular or an elliptical orifice with a circumference
dentical to the circular orifice (54). In tricuspid AV, the
hape of the stent deployment was circular (68%), triangular
21%), or elliptic (11%). In bicuspid AV, elliptical deploy-
ent was present in 79%. The incidence of gaps between
he stent external surface and the AV, in tricuspid and
icuspid AV, was 58% and 43%, respectively (p  0.49).
Comment. The high incidence of gaps is of concern.
ransapical aortic valve implantation (TAP-AVI). The
AP-AVI with the use of an Edwards SAPIEN valve
Edwards Lifesciences) was performed in 59 consecutive
atients ages 81 6 years with an average EuroSCORE for
redicted mortality of 27  14%. The TAP-AVI was
uccessfully performed in 53 patients; 4 required early
onversion to sternotomy (55). The 30-day mortality was
3.6%. Actuarial survival at 110 77 days was 75.7 5.9%
Fig. 11).
A TAP-AVI in 40 patients with the use of the
dwards SAPIEN valve (Edwards Lifesciences) was
erformed in 40 high-risk patients; 35 were successfully
Figure 10 Aortic Valve Gradients With
Percutaneous Valve Replacement
“Transaortic gradients” before and after percutaneous aortic valve replace-
ment. The pressure scale is not included. In the pre-procedure tracing (left),
LV systolic pressure is off scale. The post-procedure tracings (right) show no
delay from LV to FA (is “FA” from ascending aorta?), and the pulse pressure is
very wide, raising concern about severity of AR. FA  femoral artery; LV  left
ventricle. Reprinted, with permission, from Webb (49).eated (56). The 30-day death rate was 17.5%, and in-ospital death rate was 22.5%. The AVA increased from 0.62
0.13 cm2 to 1.61  0.37 cm2 (p  0.0001). Actuarial
urvival was 81.8  6.2% at 1 month and 71.7  7.7% at 3
onths (Fig. 12).
Comment. An in-hospital death rate that is greater than
he 30-day mortality implies that some patients had died
fter 30 days and not yet been discharged from the hospital
fter surgery.
alve-in-a-valve procedure. The CoreValve System was
sed in an 80-year-old man with severe AR in a degenerated
ioprosthetic valve. The logistic EuroSCORE was 36%
57). After 1 year, the patient was asymptomatic with good
alve-in-a-valve prosthetic function.
Comment. The suitability of EuroSCORE for estimating
ortality after valve surgery has been questioned (please see
he previous section, “Aortic Stenosis”).
mportance of echocardiography in percutaneous aortic
alve implantation (PAVI). Fifty consecutive patients
ere deemed suitable for PAVI by the use of TTE, and 37
74%) also underwent TEE (59). The authors used TTE to
etermine annular dimension and to guide correct device
izing. Using TEE, they were able to successfully guide
evice implantation in 97%, and TEE also was useful in the
etection and treatment of “significant” paravalvular AR.
he authors concluded that echocardiography has an “im-
ortant role in case selection, in guiding device placement,
nd in detecting complications” of PAVI.
valuation of aortic root by multislice computed tomog-
aphy. The use of multislice computed tomography pro-
ides information in 2 different views of aortic annulus and
ts shape (59). It also provides information on the distance
rom the annulus to the coronary ostia.
ntraventricular conduction abnormalities and the need
or permanent pacemaker implantation. Forty consecu-
ive patients who had PAVI were studied (60). Left bundle
Figure 11 Survival After Transapical Aortic
Valve Replacement: Multicenter Experience
Survival at 110  77 days after transapical minimally invasive aortic valve
replacement, a multicenter experience. Reprinted, with permission, from
Walther et al. (55). pts  patients.
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Year in Valvular Heart Disease May 19, 2009:1894–1908ranch block (BBB) was present in 15% before PAV and
5% after PAVI (p 0.0001). Two patients with right BBB
ecame dependent on a pacemaker. Temporary and perma-
ent pacemakers were needed in 20% and 18%, respectively.
Of 123 patients with PAVI, 2 patients (1.6%) required
acemaker implantation because of pre-existing intermit-
ent bradycardia, 7 (5.7%) developed complete heart block
nd needed permanent pacemakers (61), and 4 (3.3%)
eveloped left BBB.
hanges in MR with the Mitra Clip. In the Mitra Clip,
VEREST-1 (Endovascular Valve Edge-to-Edge Re-
air) study, MR was evaluated in a central echocardio-
raphic laboratory (62). Comparing pre-procedure vol-
mes to 6-month post-procedure volumes, the authors
ound that mean regurgitant volume had decreased from
0.3 to 27.5 ml (change 22.8 ml; p  0.0001),
egurgitant fraction from 44.6% to 28.9% (change
15.7%; p  0.0001), color flow grade from 3.4 to 1.8
change 1.6; p  0.0001), and pulmonary vein flow
rom 2.8 to 1.8 (change 1.0; p  0.0018).
rosthetic Heart Valve (PHV)
uidelines for reporting mortality and morbidity. Up-
ated Guidelines from the American Association for Tho-
acic Surgery, The Society of Thoracic Surgeons, and The
uropean Association for Cardio-Thoracic Surgery were
ublished in 2008 (63).
troke after cardiac valve operation. In 2,808 patients,
ges 63  15 years, the incidence of stroke was 2.2 %; the
ncidence after AVR plus MVR was 5.4%, and valve 
ABG was 3.6% (64). Brain imaging, which was positive in
4% of patients, showed ischemic stroke. Multivariate
redictors of stroke were calcified ascending aorta, LVEF
Figure 12 Survival After Transapical Aortic
Valve Replacement: U.S Experience
Survival after trans-left ventricular apex aortic valve replacement; U.S. feasibil-
ity study. Error bars at 1 standard error. Reprinted, with permission, from
Svensson et al. (56).0.30, diabetes, age70 years, and bypass time120 min. Hospital mortality in those patients with stroke was 24%
ersus 4.6%; 5-year survival was 54%, which was lower than
hose without stroke (p  0.001) (Fig. 13).
Low-dose” oral anticoagulation is better than the con-
entional dose in patients with mechanical PHV: final
eport. In ESCAT II (Early Self-Controlled Anticoagula-
ion Trial), a prospective randomized trial, the authors
valuated “low-dose” international normalized ratio of 1.8
o 2.8 for AVR and 2.5 to 3.5 for MVR compared with the
onventional international normalized ratio range of 2.5 to
.5 (65). The authors’ findings were similar to those in their
reliminary report (66).
Comment. The authors claim their preliminary report in
005 led to the lower dose recommendation by the Amer-
can College of Cardiology/American Heart Association
uidelines in 2006, which is an incorrect claim. After their
reliminary report, it was pointed out that their low dose
as similar to the American College of Cardiology/
merican Heart Association recommendation in 1998 (66),
hich preceded the preliminary report of the authors by 7
ears (1998 vs. 2005).
ood 25-year outcome after AVR with Medtronic-Hall
HV. In this study, 816 patients had AVR, and follow-up
as 99.6% complete (67). Survival at 25 years was 24.9%.
here were no mechanical failures. Older age, female sex,
nd associated CABG was associated with lower survival.
inearized rates of thromboembolic complications,
arfarin-related bleeding, and IE were 1.5%, 0.7%, and
.16% per patient year, respectively; at follow-up, 79% were
n NYHA functional classes I and II.
Comment. The patients’ conditions at baseline were not
resented. Their comorbid conditions, which are very im-
ortant factors in determining patient outcomes, were
mphasized in 1988 (68).
reater mortality with bioprosthesis in patients ages 50
o 70 years. From 1991 to 2000, 1,100 patients ages 50 to
0 years had isolated AVR CABG. Of these, 510 had St.
ude Medical mechanical and 257 Carpentier-Edwards
ioprostheses model numbers 2625 (first-generation por-
ine valve), 2700 (standard Perimount pericardial valve),
nd 2800 (reduced-sewing ring version of the 2700 valve)
69). Data were analyzed in 440 patients matched 1:1 only
y age, sex, CABG, and valve size in 220 patients in each
roup, mechanical and bioprosthesis. The “perioperative”
ortality was much greater in the bioprosthetic group (5.5%
s. 1.8%, p  0.04), who also had longer cross-clamp and
ardiopulmonary bypass time (p  0.03) and, on average,
ere 0.9 years older. Follow-up was 92% complete; for
echanical valve, it averaged 8.6 years and for bioprosthesis
.2 years. The unadjusted 5- and 10-year survival for the
echanical group was 87% (95% CI: 83% to 92%) and 68%
95% CI: 62% to 76%), respectively, and for the biopros-
hesis group it was 72% (95% CI: 66% to 78%) and 50%
95% CI: 52% to 58%, p  0.01) for both. Survival for
atched groups and total groups was “virtually identical.”
emorrhagic complications necessitating hospitalization
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May 19, 2009:1894–1908 Year in Valvular Heart Diseaseere greater in the mechanical group (15% vs. 7%, p 
.01). Freedom from reoperation was similar in the 2
roups.
Comment. This area of investigation is an important one,
ut this study has the following concerns regarding its
onclusions: 1) The VA randomized trial had shown a
etter survival after 10 years with Bjork-Shiley (Delron ring
alve) compared with the porcine valve largely because of
VD and its complications that were observed with the
orcine valve only in those 65 years of age (70). Thus,
ost patients in the present study were at risk for SVD with
ioprosthesis and, thus, at risk for greater mortality.
2) It was shown in 1988 that survival after valve replace-
ent was importantly determined by the patient’s comorbid
onditions (68). The incidence of lipid abnormalities, hy-
ertension, and the percent who had pre-operative coronary
rteriography were not presented. In the VA randomized
rial, approximately 60% of late deaths after AVR were not
elated to the prosthesis; the cause(s) of death had been
etermined by a blinded committee (70). In the present
tudy, matching was performed for only 4 baseline charac-
eristics. The much greater operative mortality and longer
ypass and cross-clamp time indicate that those in the
ioprosthesis group were at greater risk.
ole of AVR in septuagenarian’s quality of life (QOL).
total of 160 septuagenarians underwent AVR, with
ABG in 18.8% (71). “Global” hospital mortality was 8.8%.
t follow-up (mean 3.4 2.8 years), 121 were still alive and
Figure 13 Survival After Stroke in Patients After Valve Surgery
Unadjusted survival with or without stroke after valve surgery. Reprinted, with permnswered the Medical Outcomes Study Short-Form 36 tealth Survey QOL questionnaire. Importantly, mean
OL scores on each of the 7 Short-Form 36 scales were
ignificantly greater in the patients who underwent surgery
han in the general Italian matched population; only the 8th
cale (vitality domain) was not statistically significantly
reater (Fig. 14).
Comment. A previous study in octogenarians also had
imilar data with regard to QOL scores (72); it had also
hown marked improvement in patients’ functional class.
hus, most septuagenarians and octogenarians undergoing
raditional surgical AVR have a very good QOL and should
ot be denied AVR simply because of age.
ncreased mortality with composite AV and root replace-
ent (CVG). From 1986 to 2004, 122,971 patients in
he U.K. Heart Valve Registry were identified (73). The
perative mortality with CVG was greater than with
VR alone during the entire time period. Excluding
perative mortality, the 15-year survival in both groups
as similar.
Comment. In the STS database of 409,904 valve proce-
ures, the operative mortality for AVR was 5.7% and of
VG, when there was no aortic root pathology, was 9.5%
23).
Note. Procedures that require root reconstruction with-
ut root pathology include use of stentless valves, ho-
ografts (allografts), and pulmonary autografts (Ross
rinciple). The incidence of SVD with use of these
rostheses is of considerable interest (see the following
, from Filosoufi et al. (64).issionext).
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Year in Valvular Heart Disease May 19, 2009:1894–1908he use of SVD in stentless PHV, homografts, and
utografts. TORONTO STENTLESS PORCINE VALVE (SPV). From
991 to 2004, 357 patients received the Toronto SPV; there
ere 2 operative deaths. The 12-year survival was 64  4%
74). The freedom from SVD at 12 years was 69  4%; 52 
% for patients younger than 65 years of age, and 85  4%
or patients 65 years of age (p  0.002). The authors
tated the TSPV has provided “. . .suboptimal durability,
articularly in patients less than 65 years of age. We now use
his valve mostly in older patients who have a small aortic
nnulus.”
Comment. This statement from Tirone David, arguably
the father of the stentless valve,” is a powerful one.
A total of 57 patients underwent reoperation for SVD (47
ith Toronto SPV; 10 with Medtronic Free-style). Oper-
tive mortality was 11%; for redo AVR 1 year after
tentless valve implantation versus 1 year was 67% versus
% (p  0.03) (75). The authors stated that “[R]eoperation
fter stentless AVR is a challenging procedure that fre-
uently requires aortic root replacement.”
Comment. Reoperation within 1 year after AVR is
ssociated with an extremely high mortality.
ryolife O’Brien SPV. A total of 185 patients had AVR
ith the Cryolife O’Brien from 1994 to 2004 (76). Hospital
ortality was 5.4%. Actuarial survival at 5 and 10 years was
8% and 40%, respectively. Freedom from SVD at 5 and 10
ears was 91% and 44%, respectively.
Comment. This study reports a very high rate of SVD and
f mortality.
omografts (allografts). A total of 200 consecutive pa-
ients underwent subcoronary AVR (77). Operative mortal-
ty was 1.5%. Minimum follow-up was 20 years, and
aximum was 30 years. At 10, 15, 20, and 25 years, survival
Figure 14 Quality of Life After Valve
Replacement in Septuagenarians
Eight quality-of-life measures after traditional surgical aortic valve replacement
with bileaflet prosthesis in patients 70 years (mean age 73  33 years) in
Italian patients compared with Italian subjects matched for age and sex.
Reprinted, with permission, from Vicchio et al. (71).as 80.8  2.8%, 67.8  3.4%, 57.0  3.6%, and 52.0 .2%, respectively, and freedom from reoperation for any
eason was 86.5  2.6%, 70.0  3.8%, 40.3  5.1%, and
6.0  5.4%, respectively.
Comment. Patients’ age not given; data are from a
egional center (pediatric and adult patients) and a chil-
ren’s hospital.
omografts and autografts. A total of 169 consecutive
atients with congenital AV disease ages 16 to 55 years were
tudied; 63 received an autograft at age 29  9 years and
06 at age 38 10 years received homografts (78). Hospital
ortality was 3.2%. The 13-year survival for autograft
ersus allografts recipients was 94.6  2.1% versus 92.7 
.3% (p  0.45), respectively. At 13 years, freedom from
eoperation for SVD was 63.4  9.6% for autografts and
8.8  6.3% for homografts (p  0.44).
Comment. The rates of reoperation for SVD of both
HVs are high.
eprint requests and correspondence: Dr. Shahbudin H. Ra-
imtoola, University of Southern California, 2025 Zonal Avenue,
NH 7131, Los Angeles, California 90033. E-mail: rahimtoo@
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